Valganciclovir 450mg Tablet
Composition:
Each film coated tablet contains:
Valganciclovir hydrochloride USP eq. to Valganciclovir 450mg
[ We were the "first company to Launch Valganciclovir Hcl USP 450mg tablets (CMV
disease / organ transplant drug) in India as Non Infringing product against ROCHE Patent
and thereafter started manufacturing PROTHYMO(Sanofi), VEGACYTE (Panacea),
VALGACEL (Intas), VALCHEK (La Renon), CMVee (RPG), VALNICHE (Alniche) ]
Product Profile
Valganciclovir, a pro-drug of antiviral, Gancilcovir which, after oral administration, is rapidly
converted to ganciclovir by intestinal and hepatic esterases. The virustatic activity of Ganciclovir
is due to inhibition of viral DNA synthesis by: (a) competitive inhibition of incorporation of
deoxyguanosine-triphosphate into DNA by viral DNA polymerase, and (b) incorporation of
ganciclovir triphosphate into viral DNA causing termination of, or very limited, further viral DNA
elongation.
It is rapidly and extensively converted to the active ingredient Ganciclovir. Its bioavailability is
10-fold higher than from oral Gancilcovir.
Indications:
- Prevention of CMV Disease in Transplant recipients ; prevention of CMV disease in kidney, heart, and kidney-pancreas transplant recipients at high risk (CMV-seronegative recipient/CMV-seropositive donor).
- Cytomegalovirus (CMV) Retinitis and secondary prophylaxis of CMV retinitis in HIVinfected
